These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34292372)

  • 1. HBeAg-positive patients with HBsAg  < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
    Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
    J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
    Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
    BMC Gastroenterol; 2023 Jun; 23(1):224. PubMed ID: 37386460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B.
    Wang FD; Zhou J; Li LQ; Wang ML; Tao YC; Wang YH; Zhang DM; Chen EQ
    Front Microbiol; 2022; 13():901233. PubMed ID: 35814664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
    J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
    Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
    J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation.
    Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
    Dig Dis; 2023; 41(6):922-931. PubMed ID: 37586356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
    Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
    Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review.
    Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
    Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.
    Liu J; Li T; Zhang L; Xu A
    Hepatology; 2019 Sep; 70(3):1045-1055. PubMed ID: 30561829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen.
    Wu S; Li T; Liu F; Yin D; Zhang L; Wang L
    J Coll Physicians Surg Pak; 2024 May; 34(5):545-550. PubMed ID: 38720214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
    Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
    World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
    Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
    Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
    Chen YC; Hsu CW; Chien RN
    J Med Virol; 2023 Nov; 95(11):e29213. PubMed ID: 37933418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation.
    Yang SY; Hu TH; Chou YP; Kuo YH; Tsai MC; Chang KC; Yen YH; Tseng PL
    J Infect Public Health; 2023 Nov; 16(11):1852-1859. PubMed ID: 37837921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.
    Liao G; Ding X; Xia M; Wu Y; Chen H; Fan R; Zhang X; Cai S; Peng J
    Int J Gen Med; 2021; 14():4967-4976. PubMed ID: 34483685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
    Liu Y; Jia M; Wu S; Jiang W; Feng Y
    Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.